Mosińska P, Fichna J, Storr M. Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation. World J Gastroenterol 2015; 21(24): 7436-7442 [PMID: 26139989 DOI: 10.3748/wjg.v21.i24.7436]
Corresponding Author of This Article
Jakub Fichna, MD, PhD, Professor, Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland. jakub.fichna@umed.lodz.pl
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 28, 2015; 21(24): 7436-7442 Published online Jun 28, 2015. doi: 10.3748/wjg.v21.i24.7436
Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation
Paula Mosińska, Jakub Fichna, Martin Storr
Paula Mosińska, Jakub Fichna, Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, 92215 Lodz, Poland
Martin Storr, Department of Medicine, Division of Gastroenterology, Ludwig Maximilians University of Munich, 81377 Munich, Germany
Author contributions: Mosińska P, Storr M, and Fichna J designed the study; Mosińska P wrote the manuscript; Storr M and Fichna J revised the manuscript.
Supported by Iuventus Plus program of the Polish Ministry of Science and Higher Education, No. 0107/IP1/2013/72 (to JF) and the grant from the Medical University of Lodz, No. 503/1-156-04/503-01.
Conflict-of-interest: The authors have no competing interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jakub Fichna, MD, PhD, Professor, Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland. jakub.fichna@umed.lodz.pl
Telephone: +48-42-272507 Fax: +48-42-2725694
Received: November 4, 2014 Peer-review started: November 4, 2014 First decision: December 11, 2014 Revised: December 19, 2014 Accepted: January 21, 2015 Article in press: January 21, 2015 Published online: June 28, 2015 Processing time: 237 Days and 10.2 Hours
Abstract
Chronic idiopathic constipation is a common disorder of the gastrointestinal tract that encompasses a wide profile of symptoms. Current treatment options for chronic idiopathic constipation are of limited value; therefore, a novel strategy is necessary with an increased effectiveness and safety. Recently, the inhibition of the ileal bile acid transporter has become a promising target for constipation-associated diseases. Enhanced delivery of bile acids into the colon achieves an accelerated colonic transit, increased stool frequency, and relief of constipation-related symptoms. This article provides insight into the mechanism of action of ileal bile acid transporter inhibitors and discusses their potential clinical use for pharmacotherapy of constipation in chronic idiopathic constipation.
Core tip: Increasing the delivery of bile acids to the colon is considered one of the most promising treatment approaches for patients with constipation. This review discusses recent advances in the field of inhibitors of bile acid transporters and future perspectives in their clinical use.
